Palopegteriparatide
Combination ProductSubcutaneous injection for 234 weeks
Other names: Yorvipath
NCT Number: NCT07706764
This trial will enroll adolescents between ages of ≥12 and <18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it is. At least 12 participants will receive palopegteriparatide for 234 weeks. This trial will be conducted in Europe.
Interested in participating?
Request Info12 year–18 year
All sexes
Interventional
Phase 3
Ascendis Pharma Investigational Site, Bron, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneous injection for 234 weeks
Other names: Yorvipath
Time frame: 26 weeks
The multi-component endpoint is the percentage of participants who met the following criteria at Week 26: 1) albumin-adjusted serum calcium within the normal range ; 2) independence from active vitamin D, and 3) independence from therapeutic doses of calcium
Time frame: 234 weeks
The multi-component endpoint is the percentage of participants who met the following criteria: 1) albumin-adjusted serum calcium within the normal range (8.3-10.6 mg/dL) 2) independence from active vitamin D; and 3) independence from therapeutic doses of calcium.
Time frame: 234 weeks
Change from baseline and normalization of serum calcium, mmol/L
Time frame: 234 weeks
Change from baseline and normalization of serum phosphate, mmol/L
Time frame: 234 weeks
Change from baseline and normalization of serum creatinine, mL/min
Time frame: 234 weeks
Incidence of nephrolithiasis or nephrocalcinosis on renal ultrasound
Time frame: 234 weeks
Number of hospitalizations/ER/urgent care visits
Time frame: 234 weeks
Percentage of participants experiencing an adverse event
Time frame: 234 weeks
Bone mineral density measured by dual-energy x-ray absorptiometry (DXA)
Time frame: 234 weeks
Qualitative evaluation of bone turnover marker ctx (ng/L) in blood sample
Time frame: 234 weeks
Qualitative evaluation of bone turnover marker p1np (ng/mL) in blood sample
Time frame: 234 weeks
Hypoparathyroidism Patient Experience Scale (HPES) Symptom score, including Physical and Cognitive Domains
Time frame: 234 weeks
Hypoparathyroidism Patient Experience Scale (HPES) Impact score, including Physical Functioning and Daily Life Domains
Time frame: 234 weeks
Urine biochemistries to include 24-hour urine calcium
Contact information is provided by the study sponsor or research team.
Ascendis Pharma A/S
Industry
A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) With Chronic Hypoparathyroidism
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07699471
Endocrine System Diseases, Hypoparathyroidism
Homestead, Florida, United States
View Trial DetailsNCT07197450
Endocrine System Diseases, Hypoparathyroidism
Beijing, China
View Trial DetailsNCT07540286
Endocrine System Diseases, Hypoparathyroidism
Beijing, China
View Trial DetailsNCT07083557
Atherosclerotic Disease, Atrophy
Columbia, Missouri, United States
View Trial Details